Strong Growth in Key Products
Dupixent global net product sales increased by 21% to $4.3 billion, and Libtayo sales grew by 25% to $377 million on a constant currency basis compared to the previous year.
Successful Launches and Pipeline Advances
Lynozyfic was FDA approved for relapsed/refractory multiple myeloma, and several new indications for Dupixent were approved, potentially treating over 600,000 additional patients.
Robust Financial Performance
Second quarter diluted net income per share grew 12% to $12.89, and the company generated $1.7 billion in free cash flow for the first half of 2025.
Significant R&D Investments
Investments over $7 billion in the U.S. for expanding R&D and manufacturing capabilities, with a strong pipeline of approximately 45 product candidates.